Company intelligence / Profile preview

Selenity Therapeutics

Durham, NC, United Statesserenitytherapeutics.ca ↗

Ownership: Private
Development stage: Commercial

Overview

The lead asset PB‑6440 targets ALDOS for resistant hypertension and has reached Phase 1 trials. Another program SE‑7552 for multiple myeloma remains preclinical. No published clinical results are available as of January–March 2025. The company focuses on small molecule therapeutics across several disease domains including endocrinology/metabolic disorders and oncology.

Therapeutic areas: OncologyCardiovascular
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

3 assets

dexmedetomidine

Commercial

Indications: Agitation in schizophrenia, Agitation in bipolar disorder

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Selenity Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selenity Therapeutics.

Explore the full profile